Influence of TPMT and NUDT15 Genetic Polymorphisms on Mercaptopurine Pharmacokinetics in Healthy Volunteers
Genetic Testing and Molecular Biomarkers · 2024
DOI: 10.1089/gtmb.2023.0605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetic Testing and Molecular Biomarkers, 2024. Verfasst von Qihui Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Mercaptopurine, Methyltransferases, Pyrophosphatases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Aims
This study aimed to investigate the impact of genetic polymorphisms of thiopurine methyltransferase (TPMT) and NUDT15 on pharmacokinetics profile of mercaptopurine in healthy adults in China.
Methods
Blood samples were obtained from 45 healthy adult volunteers who were administered azathioprine. Genomic DNA was extracted and sequenced for TPMT and NUDT15. The plasma concentrations of 6-mercaptopurine (6-MP) were determined by ultra-performance liquid chromatography-tandem mass spectrometry. Finally, pharmacokinetic parameters were calculated based on the time-concentration curve.
Results
Among the 45 healthy adult volunteers enrolled in the study, two TPMT allelic variants and three NUDT15 allelic variants were detected. In total, six genotypes were identified, including TPMT*1/*1&NUDT15*1/*1, TPMT*1/*1&NUDT15*1/*2, TPMT*1/*1&NUDT15*1/*9, TPMT*1/*1&NUDT15*2/*5, TPMT*1/*6&NUDT15*1/*2, and TPMT*1/*3&NUDT15*1/*2. The results indicated that Area Under Curve (AUC) of 6-MP in volunteers with TPMT*1/*3&NUDT15*1/*2 and TPMT*1/*6&NUDT15*1/*2 were 1.57-1.62-fold higher than in individuals carrying the wild type (TPMT*1/*1&NUDT15*1/*1). Compared with wild type, the half-life (T1/2) of TPMT*1/*6&NUDT15*1/*2 was extended by 1.98 times, whereas T1/2 of TPMT*1/*3&NUDT15*1/*2 decreased by 67%. The maximum concentration (Cmax) of TPMT*1/*3&NUDT15*1/*2 increased significantly by 2.15-fold, whereas the corresponding clearance (CL/F) decreased significantly by 58.75%.
Conclusion
The findings of this study corroborate the notion that various genotypes of TPMT and NUDT15 can impact the pharmacokinetics of mercaptopurine, potentially offering foundational insights for personalized mercaptopurine therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
- The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou, China.
- Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd, Hangzhou, China.
- Zhejiang Aotuokang Pharmaceutical Group Inc. Co., Jinhua, Zhejiang, China.
ORCID-Profile: Ting Li
Zitieren
APA
Kong, Q., Zhang, Q., Chen, D., Lou, J., Zhu, J., Chen, M., & Li, T. (2024). Influence of TPMT and NUDT15 Genetic Polymorphisms on Mercaptopurine Pharmacokinetics in Healthy Volunteers. Genetic Testing and Molecular Biomarkers. https://doi.org/10.1089/gtmb.2023.0605
Vancouver
Kong Q, Zhang Q, Chen D, Lou J, Zhu J, Chen M, et al. Influence of TPMT and NUDT15 Genetic Polymorphisms on Mercaptopurine Pharmacokinetics in Healthy Volunteers. Genetic Testing and Molecular Biomarkers. 2024. doi:10.1089/gtmb.2023.0605
BibTeX
@article{Kong2024,
author = {Kong, Qihui and Zhang, Qiqi and Chen, Di and Lou, Jinfang and Zhu, Jian and Chen, Mingjing and Li, Ting},
title = {Influence of TPMT and NUDT15 Genetic Polymorphisms on Mercaptopurine Pharmacokinetics in Healthy Volunteers},
journal = {Genetic Testing and Molecular Biomarkers},
year = {2024},
doi = {10.1089/gtmb.2023.0605}
}
EUVIMED